Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
verify the member's current documents
Novartis is expanding the work carried out from its India development centres as the Swiss drugmaker amping up its global focus on cardio-renal-metabolic diseases, oncology, immunology and neuroscience
Cardiovascular risk markers normalize
Stimulant-based compounds such as caffeine work by activating the central nervous system, which may temporarily increase energy expenditure and reduce appetite
US$ 27.82
US$ 28.67
US$ 26.55
US$ 28.93
US$ 22.56
US$ 22.21
US$ 25.14
US$ 20.97
US$ 24.97
US$ 22.02
US$ 27.38
